From the School of Medicine, Xiamen University.
Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University.
J Clin Rheumatol. 2021 Mar 1;27(2):50-55. doi: 10.1097/RHU.0000000000001128.
BACKGROUND/OBJECTIVE: The neurological involvement associated with primary Sjögren's syndrome (pSS) can be life threatening. However, the specific characteristics of pSS-related neurological involvement remain obscure. This study aimed at determining the clinical characteristics of this neurological involvement in patients with pSS.
The clinical data of 205 patients with pSS who were admitted to our department between January 2015 and June 2017 were studied. Characteristics and laboratory findings of pSS patients with neurological abnormalities were compared with pSS patients without.
Forty of the 205 patients with pSS exhibited neurological abnormalities (19.51%); of these, 13 patients exhibited central nervous system (CNS) involvement only, 20 patients exhibited peripheral nervous system (PNS) involvement only, and 7 patients exhibited both, yielding a total of 20 (9.76%) patients with CNS involvement and 27 (13.17%) patients with PNS involvement. The titers of anti-Sjögren's syndrome type A (SSA) antibodies were significant higher while the presence of anti-Sjögren's syndrome type B (SSB) antibodies was significant lower in patients with vs. without neurological involvement. Similar results were found in patients with CNS involvement. No significant differences between patients with and without neurological involvement were found for the other clinical parameters examined.
Neurological involvement in patients with pSS is common and needs to be carefully evaluated. Patients with pSS with a high titer of anti-SSA and low presence of anti-SSB antibodies might have a relatively high risk of developing neurological involvement. Future studies should focus on identifying biomarkers that may aid in the early diagnosis of neurological involvement in patients with pSS.
背景/目的:原发性干燥综合征(pSS)相关的神经病变可能危及生命。然而,pSS 相关神经病变的具体特征尚不清楚。本研究旨在确定 pSS 患者神经病变的临床特征。
研究了 2015 年 1 月至 2017 年 6 月期间我院收治的 205 例 pSS 患者的临床资料。比较了 pSS 患者神经病变的特征和实验室检查结果。
205 例 pSS 患者中有 40 例(19.51%)存在神经病变;其中 13 例仅中枢神经系统(CNS)受累,20 例仅周围神经系统(PNS)受累,7 例同时受累,共 20 例(9.76%)CNS 受累,27 例(13.17%)PNS 受累。神经病变患者抗 Sjögren 综合征 A(SSA)抗体滴度显著升高,抗 Sjögren 综合征 B(SSB)抗体阳性率显著降低。中枢神经系统受累患者也有类似结果。未发现神经病变患者与无神经病变患者之间的其他临床参数存在显著差异。
pSS 患者的神经病变很常见,需要仔细评估。抗 SSA 抗体滴度高、抗 SSB 抗体阳性率低的 pSS 患者可能存在较高的神经病变风险。未来的研究应重点寻找有助于早期诊断 pSS 患者神经病变的生物标志物。